Showing results (21-30 of 82) with videos related to
Sort By:
Pageof 9
Frontiers in Neurology|February 4, 2021
Serum Tumor Markers in Paraneoplastic Neurologic Syndromes: A Systematic Review of GuidelinesChiara Trevisiol, Ilaria Cani, Aline S C Fabricio, et al.Clinical Chemistry and Laboratory Medicine|August 1, 2007
An Italian program of External Quality Control for chromogranin A (CgA) assay: performance evaluation of CgA determinationPaolo Verderio, Ruggero Dittadi, Ettore Marubini, et al.Clinical Breast Cancer|March 15, 2003
Prognostic and predictive indicators in operable breast cancerAlessandro Morabito, Elena Magnani, Massimo Gion, et al.Journal of the National Cancer Institute|August 18, 2005
Reporting recommendations for tumor marker prognostic studies (REMARK)Lisa M McShane, Douglas G Altman, Willi Sauerbrei, et al.Nature Clinical Practice. Oncology|September 1, 2005
REporting recommendations for tumor MARKer prognostic studies (REMARK)Lisa M McShane, Douglas G Altman, Willi Sauerbrei, et al.European Journal of Cancer (Oxford, England : 1990)|July 27, 2005
REporting recommendations for tumour MARKer prognostic studies (REMARK)Lisa M McShane, Douglas G Altman, Willi Sauerbrei, et al.Breast Cancer Research and Treatment|August 26, 2006
REporting recommendations for tumor MARKer prognostic studies (REMARK)Lisa M McShane, Douglas G Altman, Willi Sauerbrei, et al.Nature Clinical Practice. Urology|February 17, 2006
REporting recommendations for tumor MARKer prognostic studies (REMARK)Lisa M McShane, Douglas G Altman, Willi Sauerbrei, et al.International Journal of Cancer|September 24, 2004
Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-)epigallocatechin-3-gallateElga Pezzato, Luigi Sartor, Isabella Dell'Aica, et al.Clinical Chemistry and Laboratory Medicine|February 7, 2014
An epidemiology-based model to estimate the rate of inappropriateness of tumor marker requestsMassimo Gion, Roberta Franceschini, Claudia Rosin, et al.Pageof 9